No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Huakang Biomed (08622): Xu Ming has been appointed as a non-executive director.
huakang biomed (08622) announced that Xu Ming has been appointed as a non-executive director of the company, effective from October 2024...
HUAKANG BIOMED: 2024 INTERIM REPORT
Huakang Biomed (08622) announced its interim results, with a net loss of approximately 1.779 million yuan attributable to owners, a 22.27% year-on-year increase in the loss.
Huakang Biomed (08622) announced its 2024 interim performance, with revenue increasing by about 4% YoY to 11.9 million yuan...
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of Holding
